Accessibility links Skip to main content

New member onboard – Sophie Vériter

Sophie Vériter, Ph.D. in Biomedical and Pharmaceutical Sciences joins 2 Bridge as R&D Director. At 2 Bridge, she will be involved in CMC projects and scientific development activities, and support the development of innovative therapies, mainly in the field of Cell and Gene Therapy.

Contact us

Fill out the form and we will contact you shortly.

Naam
Privacy Policy 
Continue reading

Sophie is a scientist with a passion for innovative therapies to improve health and quality of life.

She has over 10 years of professional experience in the field of cell therapy in regenerative medicine. She has been involved in the creation of a Belgian biotech, Novadip Biosciences, from the academic bench to cell therapy products currently being tested in phase I/II clinical trials. Sophie led the discovery and preclinical development of innovative cell therapy products and biologics as well as early R&D activities on extracellular vesicles. More recently, she was part of the CMC and non-clinical team of a clinical-stage subsidiary of Fresenius Medical Care, Unicyte AG, focusing on the development of cell therapies and extracellular vesicles.

Flexible, dynamic, and solutions-oriented, Sophie enjoys working in a fast-paced environment where adaptability and continuous improvements are needed.

Your Partner in Quality, Safety, and Compliance

The life sciences sector requires specialized knowledge and reliable guidance. Thanks to our extensive expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.

Related services

Life science company building

HR Support and Training

Clinical R&D Consultancy

Related Articles

Regenerative medicine and therapeutic stem cell therapy to regrow damaged cells as treatment for disease for cellular treatment of injury or arthritis illness due to aging with 3D illustration.
17 Nov 2025

A deep dive into the complexity of Advanced Therapy Medicinal Products

Each ATMP is unique in its characteristics for one given indication.

18 Aug 2025

Welcome Thomas Turner

We’re delighted to welcome Thomas Turner, PhD to 2 Bridge as a Consultant – Translational Science.

06 Jun 2025

The Clinical Lead: Turning Strategy into Patient-Ready Action

What to expect in this blog 1. The Role at a Glance 2. Their Key Responsibilities 3. What Makes a Strong Clinical Lead 4. A Closer Look at Their Impact

20 May 2025

Why Every Compound Development Team Needs a Project Leader

What to expect in this blog 1. The Visionary Behind Science Understanding the Role of Project Leaders 2. The Captain’s Mission Steering the Team towards Success 3. Navigating Rough Seas The Multi-tasks of the Project Leader 4. From Vision to Value Qualifications of a Drug Development Captain

14 May 2025

How Project Management Leaders Steer Tiger Teams in Drug Development

What to expect in this blog 1. The Maestro Behind the Scenes The Role of a Project Management Leader in a Tiger Team 2. Purpose Navigating the Complexity of Drug Development 3. Responsibilities Turning Strategy into Action 4. Skillset Communication and Collaboration 5. Conclusion The Compass of a Tiger Team

22 Apr 2025

Drug Development Is Not A Solo Mission

What to expect in this blog 1. Industrial pain and challenges Thriving but also challenging life science landscape 2. Why can’t you do drug development all alone Independent of the development stage your compound is in, it takes a ‘Tiger Team’ to rocket it to the next step 3. A dynamic and agile strategy to tackle the challenges In 2013, 2 Bridge is Born From NASA’s Tiger Team to drug development: How 2 Bridge aims for the moon in pharma innovation 4. Benefits of working with a Cross-Functional Tiger Team If you are a startup, you gain… If you are an investor, you benefit from…

18 Feb 2025

2 Bridge Receives Crédit d’Impôt Recherche (CIR) Accreditation

English Announcement 2 Bridge is pleased to announce that the French Ministry of Higher Education, Research, and Innovation has officially granted the company accreditation for the Crédit d’Impôt Recherche (CIR) for the years 2024, 2025, and 2026.